Resistance to chemotherapy and radiotherapy in breast cancer is a complex phenomenon influenced by various genetic and molecular factors. Several gene mutations, protein expression patterns, and transcriptional changes have been associated with this resistance:

1. **TP53 Mutations**: TP53 is a tumor suppressor gene, and its mutations are commonly associated with resistance to both chemotherapy and radiotherapy. Mutant p53 can lead to impaired apoptosis, allowing cancer cells to survive treatment.

2. **BRCA1/BRCA2 Mutations**: While BRCA1/2 mutations are typically associated with increased sensitivity to DNA-damaging agents, secondary mutations or reversion mutations can restore BRCA function, leading to resistance, particularly to PARP inhibitors.

3. **HER2 Overexpression**: Overexpression of the HER2 protein is associated with resistance to certain chemotherapeutic agents. HER2-positive breast cancers may require targeted therapies like trastuzumab for effective treatment.

4. **PI3K/AKT/mTOR Pathway Alterations**: Mutations or activation of components in this pathway can lead to resistance by promoting cell survival and growth. Inhibitors targeting this pathway are being explored to overcome resistance.

5. **ER/PR Status**: Estrogen receptor (ER) and progesterone receptor (PR) status can influence response to hormone therapies. Changes in receptor status during treatment can lead to resistance.

6. **Multidrug Resistance Genes (e.g., ABC Transporters)**: Overexpression of ATP-binding cassette (ABC) transporters, such as P-glycoprotein (encoded by the MDR1 gene), can lead to efflux of drugs from cancer cells, reducing their efficacy.

7. **BCL-2 Family Proteins**: Overexpression of anti-apoptotic proteins like BCL-2 and BCL-XL can inhibit apoptosis, contributing to resistance to chemotherapy and radiotherapy.

8. **EMT-Related Genes**: Epithelial-mesenchymal transition (EMT) is associated with increased invasiveness and resistance. Genes involved in EMT, such as TWIST, SNAIL, and ZEB1, are often upregulated in resistant cancers.

9. **DNA Repair Genes**: Alterations in genes involved in DNA repair, such as increased expression of RAD51 or alterations in mismatch repair genes, can lead to resistance by enhancing the repair of treatment-induced DNA damage.

10. **MicroRNAs**: Dysregulation of specific microRNAs can modulate gene expression and contribute to resistance. For example, miR-21 is often upregulated in resistant breast cancer cells.

These factors can interact in complex ways, and resistance often involves multiple mechanisms. Understanding these molecular changes is crucial for developing strategies to overcome resistance and improve treatment outcomes.